Trials / Terminated
TerminatedNCT04173338
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
Phase I Study of Cabozantinib in Combination With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC), Urothelial Cancer and Advanced Malignant Mesothelioma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Augusta University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma. This study will test the safety of both drugs used together and see what effect (good or bad) it has no participants and their cancer.
Conditions
- Non Small Cell Lung Cancer
- Non-squamous Non-small-cell Lung Cancer
- Urothelial Carcinoma
- Malignant Mesothelioma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cabozantinib | start at 20mg then increase by 20mg every cycle or until there's a dose-limiting toxicity. |
| DRUG | Pemetrexed | Start with 400mg/m2, then increase and maintain 500mg/m2 unless dose-limiting toxicity. |
Timeline
- Start date
- 2020-01-23
- Primary completion
- 2022-03-28
- Completion
- 2022-03-28
- First posted
- 2019-11-21
- Last updated
- 2022-06-14
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04173338. Inclusion in this directory is not an endorsement.